<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01506076</url>
  </required_header>
  <id_info>
    <org_study_id>07446/07-08</org_study_id>
    <nct_id>NCT01506076</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg With XYZAL® Tablets 5 mg in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the Bioequivalence of Levocetirizine DiHCl Tablets 5mg&#xD;
      with XYZAL tablets 5 mg and to monitor clinical status, adverse events and laboratory&#xD;
      investigations and assess relative safety and tolerance, under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A pivotal study to compare the Bioequivalence of Levocetirizine DiHCl Tablets 5 mg of&#xD;
      Dr.Reddy's Laboratories Limited with XYZAL® Tablets 5 mg of UCB Farchim S.A. in healthy,&#xD;
      human subjects under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence is based on Cmax and AUC parameters</measure>
    <time_frame>2 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Fasting</condition>
  <arm_group>
    <arm_group_label>Levocetirizine DiHCl Tablets, 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XYZAL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>XYZAL Tablets 5 mg of UCB Farchim S.A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine DiHCl</intervention_name>
    <description>Levocetirizine DiHCl Tablets 5 mg</description>
    <arm_group_label>Levocetirizine DiHCl Tablets, 5 mg</arm_group_label>
    <arm_group_label>XYZAL</arm_group_label>
    <other_name>XYZAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects will provide written informed consent.&#xD;
&#xD;
          -  Subjects must be healthy adults within 18-45 years of age (inclusive).&#xD;
&#xD;
          -  Body mass index of ≥18.5 kg/m2 and ≤25 kg/m2, with body weight not less than 50 kg.&#xD;
&#xD;
          -  Subjects must be of normal health as determined by medical history and physical&#xD;
             examination performed within 15 days prior to the commencement of the dosing in&#xD;
             Period-I.&#xD;
&#xD;
          -  Have normal ECG, chest X-Ray and vital signs and clinically non significant changes in&#xD;
             ECG &amp; chest X-Ray.&#xD;
&#xD;
          -  Availability of subject for the entire study period and willingness to adhere to&#xD;
             protocol requirements as evidenced by written informed consent.&#xD;
&#xD;
          -  Subjects will be Non smokers or moderate smokers (less than 10 cigarettes a day) for&#xD;
             at least 6 months.&#xD;
&#xD;
          -  If subject is a female volunteer and is of child bearing potential practicing an&#xD;
             acceptable method of birth control for the duration of the study as judged by the&#xD;
             investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device(IUD),&#xD;
             or abstinence.&#xD;
&#xD;
        or is postmenopausal for at least 1 year. is surgically sterile (bilateral tubal ligation,&#xD;
        bilateral oophorectomy, or hysterectomy has been performed on the subject)&#xD;
&#xD;
        •Each female subject will be given a urine pregnancy test at screening, check-in for&#xD;
        period-1, period-2 and post study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects incapable of understanding the informed consent.&#xD;
&#xD;
          -  Subjects with BP lesser than 90/60 mm of Hg or BP greater than or equal to 140/90 mm&#xD;
             of Hg.&#xD;
&#xD;
          -  History of hypersensitivity or idiosyncratic reaction to Levocetirizine or other&#xD;
             related drugs.&#xD;
&#xD;
          -  Any evidence of impairment of renal, hepatic, gastro intestinal, lung and cardiac&#xD;
             function.&#xD;
&#xD;
          -  Subjects with a history of tuberculosis, epilepsy, asthma (during past 5 years),&#xD;
             diabetes, psychosis or glaucoma will not be eligible for the study.&#xD;
&#xD;
          -  Regular smoker who smokes more than ten cigarettes daily or has difficulty in&#xD;
             abstaining from smoking for the duration of each study period.&#xD;
&#xD;
          -  Subjects who have taken over the counter or prescribed medications, including any&#xD;
             enzyme modifying drugs or any systemic medication within the past two weeks prior to&#xD;
             prior to dosing in Period-1.&#xD;
&#xD;
          -  History of any psychiatric illness, which may impair the ability to provide written,&#xD;
             informed consent.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated, or has a history of significant&#xD;
             psychiatric disorder.&#xD;
&#xD;
          -  Subjects who have a history of alcohol or substance/ drug of abuse within the last 5&#xD;
             years.&#xD;
&#xD;
          -  Subjects with clinically significant abnormal values of laboratory parameters,&#xD;
             including positive results of HIV, HBV, HCV, RPR tests.&#xD;
&#xD;
          -  Subjects who participated in any other clinical investigation using experimental drug&#xD;
             or had bled more than 350 mL in the past 3 months.&#xD;
&#xD;
          -  Subjects who are unable to or likely to be non-compliant with protocol requirements or&#xD;
             restrictions.&#xD;
&#xD;
          -  Subjects who are intolerant to venipuncture.&#xD;
&#xD;
          -  Any subject in whom Levocetirizine Dihydrochloride is contraindicated for medical&#xD;
             reasons.&#xD;
&#xD;
          -  Female volunteers who has used implanted or injected hormonal contraceptives anytime&#xD;
             during the 6 months prior to study or used hormonal contraceptives within 14 days&#xD;
             before dosing.&#xD;
&#xD;
          -  Female volunteers demonstrating a positive pregnancy screen.&#xD;
&#xD;
          -  All female subjects will be screened for pregnancy at screening, check-in each study&#xD;
             period. Subjects with positive or inconclusive results will be withdrawn from the&#xD;
             study.&#xD;
&#xD;
          -  Female volunteers who are currently breast feeding. Female subjects who are pregnant,&#xD;
             breast-feeding or who are likely to become pregnant during the study will not be&#xD;
             allowed to participate. Female subjects of child bearing potential must either abstain&#xD;
             from sexual intercourse or use a reliable barrier method (e.g. condom, IUD) of&#xD;
             contraception during the course of the study (first dosing until last blood&#xD;
             collection) or they will not be allowed to participate.&#xD;
&#xD;
          -  Subjects with positive urine screen for drugs of abuse at the time of admission&#xD;
             check-in for each period will be excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudershan Vishwanath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vimta Labs Ltd.,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vimta Labs Ltd.,</name>
      <address>
        <city>Hyderabad</city>
        <state>A.P</state>
        <zip>500 051</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>January 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2012</study_first_posted>
  <last_update_submitted>January 6, 2012</last_update_submitted>
  <last_update_submitted_qc>January 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levocetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

